Ketamine Treatment for Chronic Fatigue

Reference TimelineLast updated FEB 28
SUMMARY

A small Rutgers-led clinical trial found that a single low-dose ketamine infusion reduced fatigue scores by an average of 21% within three days, peaking at nearly 39% after 24 hours, as reported on February 17, 2026. As of February 17, 2026: The study, involving 10 participants, showed similar improvements with midazolam, an active comparator drug, indicating early promise for ketamine but no statistically significant difference between treatments. Lead senior author Leorey Saligan noted that most patients experienced fatigue recovery and increased energy. News outlets, including The New York Post on February 14, 2026, highlighted these findings, suggesting ketamine's potential for rapid relief from chronic fatigue, warranting further research.

Timeline

Want updates on this thread?

Track this story

2026

5 updates

A small Rutgers-led clinical trial found that a single low-dose ketamine infusion reduced fatigue scores by an average of 21% within three days, peaking at nearly 39% after 24 hours. However, similar improvements were observed with midazolam, an active comparator drug, indicating that while ketamine shows early promise, the study did not find a statistically significant difference between the treatments. Lead senior author Leorey Saligan noted that most patients experienced fatigue recovery and increased energy.

via Technology Networks·Healing Maps·ClinicalTrials.gov

The New York Post published an article detailing the promising results of a study on ketamine treatment for chronic fatigue. The report highlighted that the controversial drug may provide rapid relief for millions struggling with the condition, referencing the Rutgers-led research.

via atlasketamine.com·clarus-health.com·pubmed.ncbi.nlm.nih.gov·rutgers.edu

Researchers at Rutgers Health and the National Institutes of Health published findings from a small proof-of-concept study indicating that ketamine may offer rapid relief from chronic fatigue. The study, involving 10 participants, showed a notable decrease in fatigue scores after a single low-dose ketamine infusion, justifying further research.

via atlasketamine.com·clarus-health.com·pubmed.ncbi.nlm.nih.gov·rutgers.edu

A preliminary proof-of-concept, randomized, double-blind, crossover trial assessing the anti-fatigue effects of ketamine versus midazolam was published. The study involved 10 participants with chronic fatigue-related conditions and indicated a reduction in fatigue scores with ketamine, though statistical significance was not reached due to study design limitations.

via atlasketamine.com·clarus-health.com·pubmed.ncbi.nlm.nih.gov·rutgers.edu

2024

2 updates

Research on ketamine infusions for Chronic Fatigue Syndrome (CFS) was described as being in its early stages but showing promising evidence. The research noted ketamine's anti-inflammatory properties and its potential for pain relief, which are relevant to the multifaceted symptoms of CFS.

via atlasketamine.com·clarus-health.com·pubmed.ncbi.nlm.nih.gov·rutgers.edu

Clarus Health in San Francisco discussed the potential benefits of IV ketamine for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). They highlighted ketamine's anti-inflammatory effects, its ability to calm neuroglial overactivation, and its potential to alleviate comorbid depression, suggesting it as a promising, though off-label, treatment option.

via atlasketamine.com·clarus-health.com·pubmed.ncbi.nlm.nih.gov·rutgers.edu

2020

1 update

A study published in Frontiers in Psychiatry noted that patients with depression and fatigue reported significant improvement in fatigue levels following ketamine treatments. This research suggested potential benefits for chronic fatigue syndrome (CFS) due to the overlap in symptoms and biological mechanisms.

via atlasketamine.com·clarus-health.com·pubmed.ncbi.nlm.nih.gov·rutgers.edu

2007

1 update

A French study using subcutaneous ketamine demonstrated a reduction in pain levels and an increase in blood flow in brain areas associated with pain regulation in fibromyalgia patients. This further supported the idea that ketamine could influence pain pathways relevant to chronic fatigue.

via atlasketamine.com·clarus-health.com·pubmed.ncbi.nlm.nih.gov·rutgers.edu

2000

1 update

An early study in Denmark suggested that ketamine could reduce both local and referred pain in fibromyalgia patients, indicating a potential for reducing central nervous system hyperexcitability. This early research hinted at ketamine's possible role in managing pain associated with chronic fatigue-related conditions.

via atlasketamine.com·clarus-health.com·pubmed.ncbi.nlm.nih.gov·rutgers.edu

2026

Story began · 1 month ago